IND-enabling ADME studies to predict drug-drug interaction.
Testing for mRNA and enzyme activity for a comprehensive portfolio of inducible enzymes, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, UGTs and transporters
In vitro inhibition testing for a range of drug metabolizing enzymes, including CYPs (reversible and TDI), UGTs, Oxidases (e.g., AO, MAO), and Esterases (e.g., CES, ChE)
Comprehensive Phase I/II (CYP, UGT, AO/XO, FMO, CES, SULT) enzyme identification using Gentest Supersomes®, human liver fractions and human hepatocytes, including enzyme kinetics (Km, CLint) and fm determination (selective chemical inhibition, RAF/ISEF scaling)
Customized ADME analyses for unusual drug metabolizing enzymes, custom expressions, extrahepatic tissues, and assay transfers.
Join Discovery Life Sciences at Phacilitate's Advanced Therapies Week 2025, Jan 20-23 in Dallas! Visit us at Booth 161 and join Dr. Yuki Maves' presentation on Jan 23. Supply Chain: […]
Join Discovery at Precision Medicine Tri-Con 2025.
Join Discovery at World CB & CDx Summit Europe 2025.
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
